

lethal factor (LF) binding site has been modified so that only a modified PrAg comprising two different monomers can bind anthrax LF. When administered with an effector component, the recombinant anthrax toxins are toxic only to cells expressing both a MMP and uPA on their surface. This technology is therefore useful for selective methods of treating cancers, because many cancer cells express multiple cell-surface proteases.

#### **Novel Human Cancer Antigen, NY ESO-1/CAG-3, and Gene Encoding Same**

Rong-fu Wang (EM), Steven A. Rosenberg (NCI)

U.S. Provisional Application No. 60/061,428 filed 08 Oct 1997 (DHHS Reference No. E-265-1997/0-US-01); PCT Application No. PCT/US98/19609 filed 21 Sep 1998, which published as WO 99/18206 on 15 Apr 1999 (DHHS Reference No. E-265-1997/0-PCT-02); U.S. Patent Application No. 09/529,206 filed 21 Sep 1998 (DHHS Reference No. E-265-1997/0-US-04)

*Licensing Contact:* Jesse Kindra; (301) 435-5559; [kindraj@mail.nih.gov](mailto:kindraj@mail.nih.gov).

The current invention embodies the identification, isolation and cloning of a gene encoding a novel tumor antigen, NY ESO-1/CAG-3, as well as cancer peptides thereof and antigenic cancer epitopes contained within the cancer peptides. This novel antigen is recognized by cytotoxic T lymphocyte clones derived from the TIL586 (tumor infiltrating lymphocyte) cell line in an HLA restricted manner.

The inventors believe that cancer peptides which are encoded by the NY ESO-1/CAG-3 gene represent potential cancer vaccines, protecting an individual from development of cancer by inhibiting the growth of cells or tumors which express the NY ESO-1/CAG-3 antigen. Also embodied in the invention are pharmaceutical compositions comprising the NY ESO-1/CAG-3 antigen, peptide, or an antigenic cancer epitope thereof in combination with one or more immunostimulatory molecules. These compositions represent potential anticancer therapeutics, stimulating NY ESO-1/CAG-3-specific T cells to elicit an anti-cancer immunogenic response and thereby eliminating or reducing the cancer. While these vaccines and pharmaceutical compositions may be developed for use against a variety of cancers, data obtained to date indicate that they may be of particular value for use against melanoma.

Methods for diagnosing cancer via the detection of NY ESO-1/CAG-3 are also embodied in the invention.

#### **Method for Inhibiting Angiogenesis**

Elise C. Kohn, Lance A Liotta, and Riccardo Alessandro (NCI)  
U.S. Patent No. 5,744,492 issued 28 Apr 1998 (expires 28 Apr 2015) (DHHS Reference No. E-220-1993/1-US-01)  
*Licensing Contact:* John Stansberry; (301) 435-5236; [stansbej@mail.nih.gov](mailto:stansbej@mail.nih.gov) and

#### **Combinatorial Therapy for Protein Signaling Diseases**

Arpita Mehta (NCI), Lance Liotta (NCI), Emmanuel Petricoin (FDA)  
U.S. Provisional Application No. 60/453,629 filed 10 Mar 2003 (DHHS Reference No. E-039-2003/0-US-01)  
*Licensing Contact:* Michael Shmilovich; (301) 435-5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

Angiogenesis is a composite of regulated proliferation and regulated invasion occurring in a variety of normal and pathologic conditions. In this invention, the claimed compound and its related analogs are useful for inhibiting angiogenesis in a host and offer a novel approach to the treatment of cancer, diabetic retinopathy, hemangiomas, vasculidities, macular degeneration and other disease associated with angiogenesis. Additionally, the compound has shown efficacy at lower doses when co-administered with other anti-angiogenesis agents.

Refer to issued patent 5,744,492 (April 28, 1998), and journal articles: *PNAS* (1995) 92(5):1307-11, and *In Vivo* (1996) 10(2):153-60.

Dated: October 22, 2004.

#### **Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-24166 Filed 10-28-04; 8:45 am]

**BILLING CODE 4140-01-P**

### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

#### **National Institutes of Health**

#### **Notice of Meeting; Interagency Autism Coordinating Committee**

The National Institutes of Health (NIH) hereby announces a meeting of the Interagency Autism Coordinating Committee (IACC) to be held on November 19, 2004, on the NIH campus in Bethesda, Maryland.

The Children's Health Act of 2000 (Pub. L. 106-310), Title I, Section 104, mandated the establishment of an IACC

to coordinate autism research and other efforts within the Department of Health and Human Services. In April 2001, Secretary Tommy Thompson delegated the authority to establish the IACC to the NIH. The National Institute of Mental Health (NIMH) at the NIH has been designated the lead for this activity.

The IACC meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person listed below in advance of the meeting.

*Name of Committee:* Interagency Autism Coordinating Committee.

*Date:* November 19, 2004.

*Time:* 9 a.m.-4:30 p.m.

*Agenda:* Discussion of autism activities across Federal agencies.

*Place:* National Institutes of Health, 31 Center Drive, Building 31, Conference Room 10 (6th floor), Bethesda, Maryland 20892.

*Contact Person:* Ann Wagner, Ph.D., Division of Services and Intervention Research, National Institute of Mental Health, NIH, 6001 Executive Boulevard, Room 7142, MSC 9633, Bethesda, Maryland 20892. E-mail: [wagner@mail.nih.gov](mailto:wagner@mail.nih.gov). Phone: 301-443-4283.

Any member of the public interested in presenting oral comments to the Committee may notify the contact person listed on this notice at least 5 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Presentations may be limited to 5 minutes; both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the Committee by forwarding his/her statement to the contact person listed on this notice. The statement should include the name, address, telephone number, and, when applicable, the business or professional affiliation of the interested person.

Information about the meeting and online registration forms are also available on-line on the NIMH home page at <http://www.nimh.nih.gov/autismiacc/index.cfm>.

Dated: October 20, 2004.

#### **Raynard S. Kington,**

*Deputy Director, National Institutes of Health.*

[FR Doc. 04-24168 Filed 10-28-04; 8:45 am]

**BILLING CODE 4140-01-P**